Open-label trial to determine the long-term safety of safinamide in Parkinson's disease patients09/01/2011 - 08/31/2012 (PI)
Serono Inc
A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopat09/01/2010 - 08/31/2011 (PI)
Serono Inc